Literature DB >> 17629049

Predictors of tumor downsizing and regression with preoperative radiotherapy alone and with concomitant tegafur/uracil (UFT) for resectable advanced rectal adenocarcinoma.

Sotaro Sadahiro1, Toshiyuki Suzuki, Yuji Maeda, Yoichi Tanaka, Tomoki Nakamura, Takeshi Saguchi, Seiei Yasuda, Hiroyasu Makuuchi, Chieko Murayama, Yukio Ohizumi.   

Abstract

BACKGROUND/AIMS: Predictors of sensitivity to preoperative radiotherapy (RT) may differ from those of chemo-radiotherapy (CRT). This study attempts to evaluate retrospectively the significance of apoptosis-related and proliferative indexes in biopsy specimens obtained before treatment as predictors of sensitivity to RT or to CRT for locally advanced rectal adenocarcinoma.
METHODOLOGY: The subjects were 96 patients with clinical T3-4/Nx/M0 adenocarcinoma of the middle third or lower third of the rectum. Sixty-one patients were treated with preoperative RT alone (20 Gy in 10 fractions) [RT group] during 1991-1998, and 35 patients received concurrent oral tegafur/uracil (UFT) [CRT group] since 1999. Radical surgery including TME and pelvic nerve preservation with 15 Gy of intraoperative RT was performed two weeks after completion of the preoperative radiation. We evaluated apoptotic index (AI) and p53, p21 and Ki-67 protein expression in the biopsy specimens, and histological differentiation, pathologic regression in the resected specimens and the degree of tumor shrinkage based on the double contrast barium enema images.
RESULTS: AI-positivity, p53-negativity, p21-positivity and well differentiated adenocarcinoma were predictors of high sensitivity in RT group, whereas AI-positivity alone was the predictor in CRT group. The addition of UFT to RT increased sensitivity in patients with p53-positivity, p21-negativity and moderately differentiated adenocarcinoma.
CONCLUSIONS: Predictors of sensitivity are different between RT and CRT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629049

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Kazuaki Hiroishi; Masafumi Inomata; Kenji Kashima; Kazuhiro Yasuda; Norio Shiraishi; Shigeo Yokoyama; Seigo Kitano
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

2.  Survivin expression can predict the effect of chemoradiotherapy for advanced lower rectal cancer.

Authors:  Chie Takasu; Mitsuo Shimada; Nobuhiro Kurita; Takashi Iwata; Hirohiko Sato; Masanori Nishioka; Shinya Morimoto; Kozo Yoshikawa; Tomohiko Miyatani; Hideya Kashihara; Tohru Utsunomiya; Hisanori Uehara
Journal:  Int J Clin Oncol       Date:  2012-08-31       Impact factor: 3.402

3.  Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer.

Authors:  Kazushige Kawai; Joji Kitayama; Nelson H Tsuno; Eiji Sunami; Toshiaki Watanabe
Journal:  Int J Colorectal Dis       Date:  2012-10-19       Impact factor: 2.571

4.  Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets.

Authors:  Noriko Tada; Kazushige Kawai; Nelson H Tsuno; Soichiro Ishihara; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Koji Oba; Toshiaki Watanabe
Journal:  World J Surg Oncol       Date:  2015-02-07       Impact factor: 2.754

5.  P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.

Authors:  Min-Bin Chen; Xiao-Yang Wu; Rong Yu; Chen Li; Li-Qiang Wang; Wei Shen; Pei-Hua Lu
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

6.  Biological predictors of survival in stage II colorectal cancer.

Authors:  Yoshitake Ueda; Kazuhiro Yasuda; Masafumi Inomata; Norio Shiraishi; Shigeo Yokoyama; Seigo Kitano
Journal:  Mol Clin Oncol       Date:  2013-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.